Pacific Edge slumps 89.9% on Novitas decision

Pacific Edge slumps 89.9% on Novitas decision
The company still believes that it can still deliver. (Image: Pacific Edge).
Rebecca Howard
Shares of Pacific Edge plunged 89.9% on news that Medicare coverage of Cxbladder tests in the US is expected to cease from July 17.The shares resumed trading at 5 cents, having been halted on Tuesday at 49.5 cents while management worked through the implications of the decision.That wiped out $360.6 million of value as investors put a market price of $40.5m on Pacific Edge.  Over the coming days Pacific Edge will seek to explore all available legal options, including a potential appeal, with its US-based lawyers, the company said.A so-call...

More Markets

Xero CEO: AI must be functional, not just cute
Markets

Xero CEO: AI must be functional, not just cute

Xero announces suite of updates to its agentic AI tool JAX at Xerocon.

Why Xero's CEO 'wakes up thinking like an owner'
Markets

Why Xero's CEO 'wakes up thinking like an owner'

Sukhinder Singh Cassidy says she's taken a long-term bet on Xero.

Why Smiths City will struggle to find a buyer
Retail

Why Smiths City will struggle to find a buyer

Rod Duke's answer to whether he would be interested in Smith City was simple: ‘No’.

No spring in the kiwi's step
Markets

No spring in the kiwi's step

The NZD/USD is trading around 6% lower than when spring began last year.